Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
10 "Hyo Jin Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.292
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by  
  • Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
    Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
    The Oncologist.2025;[Epub]     CrossRef
  • From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu, Chunli Jing, Fandou Kong
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • SOX17 expression in ovarian clear cell carcinoma
    Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
    Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
    Li Shuqing, Zhu Zhiling
    Cancer Medicine.2023; 12(6): 6668.     CrossRef
  • Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
    Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
    Current Medical Research and Opinion.2023; 39(6): 901.     CrossRef
  • The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
    Yuan Zhuang, Hua Yang
    Cancer Control.2023;[Epub]     CrossRef
  • Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara
    Japanese Journal of Clinical Oncology.2023; 53(8): 664.     CrossRef
  • Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
    Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
    Yang Gao, Wei Ding, Pengpeng Qu
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • A clearer view on ovarian clear cell carcinoma
    Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
    Acta Clinica Belgica.2022; 77(4): 792.     CrossRef
  • Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
    Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
    Archives of Gynecology and Obstetrics.2022; 305(5): 1279.     CrossRef
  • Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
    Peng Chen, Chi-Yuan Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
    Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
    Medicine.2022; 101(37): e30666.     CrossRef
  • Clear cell carcinoma of the ovary: a clinical and molecular perspective
    Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
    International Journal of Gynecological Cancer.2021; 31(4): 605.     CrossRef
  • Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
    BMC Cancer.2021;[Epub]     CrossRef
  • The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
    Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
    Journal of Surgery and Medicine.2021; 5(8): 1.     CrossRef
  • Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
    Qian Chen, Shu Wang, Jing-He Lang
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • 8,989 View
  • 421 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Special Article
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(3):851-860.   Published online June 7, 2019
DOI: https://doi.org/10.4143/crt.2019.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by  
  • Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia
    Ljerka Armano, Vanja Vasiljev, Tomislav Rukavina, Denis Juraga, Aleksandar Racz, Vanja Tešić
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
    H Çelik, H Aslan
    Nigerian Journal of Clinical Practice.2024; 27(4): 415.     CrossRef
  • Complementary and alternative medicine use and its impact on quality of life among cancer patients in Freetown, Sierra Leone: considerations for a resource-limited setting
    Onome T. Abiri, Matilda Seinya Sheriff, Isaac O. Smalle, Nellie V.T. Bell, Ibrahim Franklyn Kamara, Thaim B. Kamara, Constance Cummings-John, Joshua Coker, Abdulai Jawo Bah, Joseph Sam Kanu, Ronita Luke, Lannes Kamara, John Smith, Mohamed Samai
    Discover Medicine.2024;[Epub]     CrossRef
  • Cancer care beyond the conventional: Challenges of integrative oncology in India
    Parvathy Venate, Vitthal G. Huddar
    Ayush Journal of Integrative Oncology.2024; 1(3 & 4): 35.     CrossRef
  • Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
    Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
    Complementary Therapies in Medicine.2023; 72: 102920.     CrossRef
  • Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
    Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
    Cancer Research and Treatment.2023; 55(2): 442.     CrossRef
  • Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
    Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
    Journal of Integrative Medicine.2023; 21(4): 377.     CrossRef
  • Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
    Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
    Journal of Community Health.2022; 47(2): 284.     CrossRef
  • Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
    Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
    Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
    Jeongwon Yeom, Jung Mi Lee
    Clinical Nutrition Research.2022; 11(4): 255.     CrossRef
  • Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
    Kyeore Bae
    The Journal of Internal Korean Medicine.2022; 43(6): 1075.     CrossRef
  • Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
    Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
    Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122.     CrossRef
  • Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
    Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
    Cukurova Medical Journal.2021; 46(2): 574.     CrossRef
  • The Current Status of Integrative Oncology in Korea
    Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
    Integrative Cancer Therapies.2021;[Epub]     CrossRef
  • Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
    Kathryn Knecht, David Kinder, Amy Stockert
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
    Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • 9,379 View
  • 225 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Original Articles
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(4):1578-1588.   Published online April 16, 2019
DOI: https://doi.org/10.4143/crt.2018.671
AbstractAbstract PDFPubReaderePub
Purpose
Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials and Methods
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).
Conclusion
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Citations

Citations to this article as recorded by  
  • A perspective on the application of macrocyclic design strategies in antitumor drugs
    Yan-Hong Li, Yu-Kang Lin, Jian-Fan Cai, Zhong-Kai Zou, Pei-Liang Zhao
    Bioorganic Chemistry.2025; 156: 108190.     CrossRef
  • Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
    Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
    International Journal of Cancer.2024; 154(6): 947.     CrossRef
  • Cancer stem cells and angiogenesis
    Yanru Yang, Jingyu Guo, Mingyang Li, Guangxin Chu, Hai Jin, Jing Ma, Qingge Jia
    Pathology - Research and Practice.2024; 253: 155064.     CrossRef
  • Renal cancer: signaling pathways and advances in targeted therapies
    Aimin Jiang, Jinxin Li, Ziwei He, Ying Liu, Kun Qiao, Yu Fang, Le Qu, Peng Luo, Anqi Lin, Linhui Wang
    MedComm.2024;[Epub]     CrossRef
  • Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
    Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Jingyang Lin, Qingxia Fang, Xiaochun Zheng, Meng Li
    PLOS ONE.2023; 18(2): e0281402.     CrossRef
  • Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
    Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
    Kidney Cancer.2023; 7(1): 123.     CrossRef
  • 8,134 View
  • 184 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park
Cancer Res Treat. 2018;50(4):1252-1259.   Published online January 2, 2018
DOI: https://doi.org/10.4143/crt.2017.438
AbstractAbstract PDFPubReaderePub
Purpose
Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC).
Materials and Methods
This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500 mg/day (5-days-on/2-days-off schedule). The primary endpointwas 16-week progression-free survival (PFS). Secondary endpoints were overall survival (OS), toxicity and prostate-specific antigen (PSA) response rate. Biomarker analyses for VEGFR2, FGF23, and FGFR2 using multiplex enzyme-linked immunosorbent assay was performed.
Results
Forty-four men were accrued from 11 hospitals. Eighty percent were post-docetaxel. Median PSA was 100 ng/dL, median age was 69, 82% had bone metastases, and 23% had liver metastases. Median cycles of dovitinibwas 2 (range, 0 to 33). Median PFSwas 3.67 months (95% confidence interval [CI], 1.36 to 5.98) and median OS was 13.70 months (95% CI, 0 to 27.41). Chemotherapy-naïve patients had longer PFS (17.90 months; 95% CI, 9.23 to 28.57) compared with docetaxel-treated patients (2.07 months; 95% CI, 1.73 to 2.41; p=0.001) and the patients with high serum VEGFR2 level over median level (7,800 pg/mL) showed longer PFS compared with others (6.03 months [95% CI, 4.26 to 7.80] vs. 1.97 months [95% CI, 1.79 to 2.15], p=0.023). Grade 3 related adverse events were seen in 40.9% of patients. Grade 1-2 nausea, diarrhea, fatigue, anorexia, and all grade thrombocytopenia are common.
Conclusion
Dovitinib showed modest antitumor activity with manageable toxicities in men with mCRPC. Especially, patients who were chemo-naïve benefitted from dovitinib.

Citations

Citations to this article as recorded by  
  • Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
    Manish Chaudhary, Shubham Kumar, Paranjeet Kaur, Sanjeev Kumar Sahu, Amit Mittal
    Mini-Reviews in Medicinal Chemistry.2024; 24(7): 721.     CrossRef
  • Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response
    Maddison Archer
    American Journal of Clinical and Experimental Urology.2024; 12(6): 331.     CrossRef
  • Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
    Alessio Ardizzone, Valentina Bova, Giovanna Casili, Alberto Repici, Marika Lanza, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Salvatore Cuzzocrea, Emanuela Esposito, Irene Paterniti
    Cells.2023; 12(7): 1002.     CrossRef
  • Case Report of a Glioma Patient with Homozygous Missense Amino Acid Substitution in KDR Gene
    Kalyan Ram Uppaluri, Himavanth Reddy Kambalachenu, Hima Jyothi Challa, Saadvik Raghuram Y., Deepak Sharma, Ramya Gadicherla, Srinivas Ketavath, Kalyani Palasamudram, Sri Manjari K.
    Indian Journal of Medical and Paediatric Oncology.2023; 44(03): 356.     CrossRef
  • FGFR families: biological functions and therapeutic interventions in tumors
    Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang
    MedComm.2023;[Epub]     CrossRef
  • Targeting transforming growth factor‐ß signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin
    Devesh Tewari, Anu Priya, Anusha Bishayee, Anupam Bishayee
    Clinical and Translational Medicine.2022;[Epub]     CrossRef
  • Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines
    Katharina Klose, Eva‐Maria Packeiser, José‐Luis Granados‐Soler, Marion Hewicker‐Trautwein, Hugo Murua Escobar, Ingo Nolte
    Veterinary and Comparative Oncology.2022; 20(3): 641.     CrossRef
  • Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy
    Elizabeth Liow, Nicholas Howard, Chol-Hee Jung, Bernard Pope, Bethany K. Campbell, Anne Nguyen, Michael Kerger, Jonathan B. Ruddle, Angelyn Anton, Benjamin Thomas, Kevin Chu, Philip Dundee, Justin S. Peters, Anthony J. Costello, Andrew S. Ryan, Christophe
    Clinical Genitourinary Cancer.2022; 20(5): 452.     CrossRef
  • There are gremlins in prostate cancer
    Laura A. Sena, W. Nathaniel Brennen, John T. Isaacs
    Nature Cancer.2022; 3(5): 530.     CrossRef
  • Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
    Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
  • Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
    Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Pankaj Sonawane, Harshali Paliwal, Suresh Thareja, Prateek Pathak, Maria Grishina, Mariusz Jaremko, Abdul-Hamid Emwas, Jagat Pal Yadav, Amita Verma, Habibullah Khalilullah, Pradeep Kumar
    Pharmaceuticals.2022; 15(9): 1071.     CrossRef
  • The FGF/FGFR system in the physiopathology of the prostate gland
    Arianna Giacomini, Elisabetta Grillo, Sara Rezzola, Domenico Ribatti, Marco Rusnati, Roberto Ronca, Marco Presta
    Physiological Reviews.2021; 101(2): 569.     CrossRef
  • Signaling Pathways That Control Apoptosis in Prostate Cancer
    Amaal Ali, George Kulik
    Cancers.2021; 13(5): 937.     CrossRef
  • A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
    Fionnuala Crowley, Michelle Sterpi, Conor Buckley, Lauren Margetich, Shivani Handa, Zach Dovey
    Research and Reports in Urology.2021; Volume 13: 457.     CrossRef
  • Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
    F.J. Sherida H. Woei-A-Jin, Nir I. Weijl, Mark C. Burgmans, Arantza Fariña Sarasqueta, J. Tom van Wezel, Martin N.J.M. Wasser, Minneke J. Coenraad, Jacobus Burggraaf, Susanne Osanto
    The Oncologist.2021; 26(10): 854.     CrossRef
  • Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment
    Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, Toru Tanaka, Yuquan Tong, Raphael I. Benhamou, Jared Baisden, Gogce Crynen, Samantha M. Meyer, Michael D. Cameron, Arnab K. Chatterjee, Alexander Adibekian, Jessica L. Childs-Disney, Matthew D. Disney
    Journal of the American Chemical Society.2021; 143(33): 13044.     CrossRef
  • Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer
    Clara H. Lee, Ann M. Decker, Frank C. Cackowski, Russell S. Taichman
    Cell Biology and Toxicology.2020; 36(2): 115.     CrossRef
  • Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD
    Lele Li, Manhui Zhu, Wenli Wu, Bai Qin, Jiayi Gu, Yuanyuan Tu, Jianing Chen, Dong Liu, Yunwei Shi, Xiaojuan Liu, Aimin Sang, Dongmei Ding
    Journal of Cellular Physiology.2020; 235(2): 1259.     CrossRef
  • In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
    Arabinda Das, Jaime L. Martinez Santos, Mohammed Alshareef, Guilherme Bastos Ferreira Porto, Libby Kosnik Infinger, William A. Vandergrift, Scott M. Lindhorst, Abhay K. Varma, Sunil J. Patel, David Cachia
    Cancer Investigation.2020; 38(6): 349.     CrossRef
  • Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma
    Ling Zhang, Xia Niu, Yanghui Bi, Heyang Cui, Hongyi Li, Xiaolong Cheng
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer


    Adam M. Kase, John A. Copland, Winston Tan
    OncoTargets and Therapy.2020; Volume 13: 10499.     CrossRef
  • Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)
    Hong Luo, Tao Zhang, Peng Cheng, Dong Li, Oleksandr Ogorodniitchouk, Chaimaa Lahmamssi, Ge Wang, Meiling Lan
    Oncology Letters.2020; 20(3): 2525.     CrossRef
  • Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
    Yi-Han Chiu, Yi-Yen Lee, Kuo-Chin Huang, Cheng-Chi Liu, Chen-Si Lin
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis
    Niko Kemi, Maarit Eskuri, Joonas H. Kauppila
    Scientific Reports.2019;[Epub]     CrossRef
  • Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
    Dan Wang, Li Yang, Weina Yu, Yi Zhang
    Expert Opinion on Investigational Drugs.2019; 28(10): 903.     CrossRef
  • A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance
    Jacqueline Olender, Bi-Dar Wang, Travers Ching, Lana X. Garmire, Kaitlin Garofano, Youngmi Ji, Tessa Knox, Patricia Latham, Kenneth Nguyen, Johng Rhim, Norman H. Lee
    Molecular Cancer Research.2019; 17(10): 2115.     CrossRef
  • Recent Advances in Prostate Cancer Treatment and Drug Discovery
    Ekaterina Nevedomskaya, Simon J. Baumgart, Bernard Haendler
    International Journal of Molecular Sciences.2018; 19(5): 1359.     CrossRef
  • 11,145 View
  • 246 Download
  • 29 Web of Science
  • 27 Crossref
Close layer
Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
Kyung A Kwon, Sung Yong Oh, Ho Young Kim, Hyo Song Kim, Ha Young Lee, Tae Min Kim, Ho Yeong Lim, Na-Ri Lee, Hyo Jin Lee, Sook Hee Hong, Sun Young Rha
Cancer Res Treat. 2014;46(2):141-147.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.141
AbstractAbstract PDFPubReaderePub
Purpose

Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.

Materials and Methods

From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.

Results

Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.

Conclusion

CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

Citations

Citations to this article as recorded by  
  • Collecting Duct Carcinoma: Characteristics and Survival outcomes from UroCCR database (CDCSurv UroCCR n°141)
    Dr Louis-Pacôme LE MEVEL, Pr Jean-Christophe BERNHARD, Dr Mokrane YACOUB, Dr Thibaut WAECKEL, Dr Céline BAZILLE, Dr Cécile CHAMPY, Dr Maria MAMODALY, Pr Karime BENSALAH, Pr Nathalie RIOUX-LECLERCQ, Dr Constance MICHEL, Dr Ilhem HERGLI, Dr Louis SURLEMONT,
    Clinical Genitourinary Cancer.2025; : 102305.     CrossRef
  • Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports
    Sang Bin Bae, Seong Kuk Yoon, Seo-hee Rha
    Journal of the Korean Society of Radiology.2024; 85(1): 222.     CrossRef
  • A curious case: Concurrent collecting duct renal cell carcinoma and upper tract urothelial carcinoma
    Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
    Urology Case Reports.2024; 54: 102698.     CrossRef
  • Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning
    Tianyi Shi, Xiucai Ye, Dong Huang, Tetsuya Sakurai
    Methods.2024; 231: 144.     CrossRef
  • Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
    Zoé Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, François Audenet, Yann-Alexandre Vano, Stéphane Oudard, Constance Thibault
    Bulletin du Cancer.2023; 110(4): 450.     CrossRef
  • Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
    Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu
    Cancers.2022; 14(7): 1678.     CrossRef
  • Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists
    Benjamin Laguna, Antonio C. Westphalen, C. T. Guimarães, Zhen Whang, Jeff Simko, Ronald Zagoria
    Abdominal Radiology.2019; 44(4): 1430.     CrossRef
  • Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors
    A. Pinto, M. Garrido, C. Aguado, T. Alonso, P. Gajate, C. Maximiano, I. García-Carbonero, A. Martín, I. Gallegos, J.A. Arranz, J. Puente, E. Grande
    Kidney Cancer.2019; 3(3): 177.     CrossRef
  • Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
    Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal
    Kidney Cancer.2017; 1(2): 99.     CrossRef
  • Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
    Gabriel G. Malouf, Eva Compérat, Hui Yao, Roger Mouawad, Veronique Lindner, Nathalie Rioux-leclercq, Virginie Verkarre, Xavier Leroy, Linda Dainese, Marion Classe, Jean-Luc Descotes, Philippe Barthelemy, Mokrane Yacoub, Morgan Rouprêt, Jean-Christophe Ber
    Scientific Reports.2016;[Epub]     CrossRef
  • Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases
    ZHENSHAN SHI, QIAN ZHUANG, RUIXIONG YOU, YUEMING LI, JIAN LI, DAIRONG CAO
    Oncology Letters.2016; 11(1): 261.     CrossRef
  • Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation
    Jianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Qiang Hu, Kiersten Marie Miles, Jeffrey M. Conroy, Sean T. Glenn, Manuela Costantini, Cristina Magi-Galluzzi, Sabina Signoretti, Toni Choueiri, Michele Gallucci, Steno Se
    Oncotarget.2016; 7(21): 29901.     CrossRef
  • 11,954 View
  • 73 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Case Reports
A Case of Non-Hodgkin's Lymphoma in Patient with Coombs' Negative Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura
So Yeon Park, Soyon Kim, Eun Sil Kim, Soon Uk Choi, Hee Jae Hyun, Ju Young Ahn, Ju Hyoung Lee, Seo Hee Ryu, Jae Hyun Park, Gyeong In Lee, Hyo Jin Lee
Cancer Res Treat. 2012;44(1):69-72.   Published online March 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.1.69
AbstractAbstract PDFPubReaderePub
Coombs' negative autoimmune hemolytic anemia (AIHA) is a rare disease which shares similar clinical and hematological features with Coombs' positive AIHA, but its exact frequency remains unknown. There have been few reports of idiopathic thrombocytopenic purpura (ITP) and Coombs' negative AIHA associated with other lymphoproliferative disorders (LPDs). Since there is a well known association between LPDs and autoimmune phenomena, it is important to investigate the possibility of an underlying malignancy. We report a case of ITP and Coombs' negative AIHA associated with diffuse large B-cell lymphoma.

Citations

Citations to this article as recorded by  
  • Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review
    Yuya Kurihara, Kazuki Taoka, Eri Takagi, Kazuhiro Toyama, Kumi Nakazaki, Mineo Kurokawa
    Internal Medicine.2021; 60(10): 1583.     CrossRef
  • Primary, secondary or less frequent causes of immune thrombocytopenia: A case report
    Minodora Onisâi, Ana-Maria Vlădăreanu, Iuliana Iordan, Horia Bumbea, Mihaela Găman, Cristina Ciufu, Irina Voican, Diana Cîșleanu, Daniela Vasile, Cristina Marinescu, Anca Nicolescu, Andreea Spînu, Raluca Nistor, Adrian Alexandru
    Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
  • Successful Treatment of Aggressive Mature B-cell Lymphoma Mimicking Immune Thrombocytopenic Purpura
    Koya Ono, Yasushi Onishi, Masahiro Kobayashi, Satoshi Ichikawa, Shunsuke Hatta, Shotaro Watanabe, Yoko Okitsu, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae
    Internal Medicine.2018; 57(17): 2573.     CrossRef
  • Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis
    Yuzuru Hosoda, Hiroshi Hagino, Norihiko Hino, Toru Motokura
    Molecular and Clinical Oncology.2017; 7(5): 855.     CrossRef
  • Synchronous Occurrence of Diffuse Large B-cell Lymphoma of the Duodenum and Gastrointestinal Stromal Tumor of the Ileum in a Patient with Immune Thrombocytopenic Purpura
    Tohru Takahashi, Yumiko Maruyama, Mayuko Saitoh, Hideto Itoh, Mitsuru Yoshimoto, Masayuki Tsujisaki, Masato Nakayama
    Internal Medicine.2016; 55(20): 2951.     CrossRef
  • Clinical and reference lab characteristics of patients with suspected direct antiglobulin test (DAT)-negative immune hemolytic anemia
    M.S. Karafin, G.A. Denomme, M. Schanen, J.L. Gottschall
    Immunohematology.2015; 31(3): 108.     CrossRef
  • 13,981 View
  • 115 Download
  • 6 Crossref
Close layer
A Case of Medullary Thyroid Carcinoma in which the Skin Metastasis was Concurrently Present and Response Occurred to Chemotherapy
Won Je Choi, Yun Young Lee, Soyon Kim, Yun Kwon Kim, Eun Sil Kim, Seung O Seo, Jae Hyun Jo, Seung Min Lee, Hyo Jin Lee
Cancer Res Treat. 2008;40(4):202-206.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.202
AbstractAbstract PDFPubReaderePub

Medullary thyroid carcinoma accounts for 3% of all thyroid gland malignancies. It commonly metastasizes to liver, lung, and bone. It rarely metastasizes to skin, and only a few such cases have been documented. Cutaneous metastasis suggests a poor prognosis, with a mean survival of 7.5-19 months. The most effective treatment for skin metastasis is complete surgical removal of all local and regional lesions. The response to systemic chemotherapy is typically poor. We report a case of medullary thyroid carcinoma with cutaneous metastases, which responded to chemotherapy.

Citations

Citations to this article as recorded by  
  • Thyroid Cancer With Cutaneous Metastases
    Bao Y. Sciscent, Hanel W. Eberly, Neerav Goyal, David Goldenberg
    Ear, Nose & Throat Journal.2024;[Epub]     CrossRef
  • Cutaneous Metastasis of Medullary Carcinoma Thyroid Masquerading as Subcutaneous Nodules Anterior Chest and Mandibular Region
    Rahul Mannan, Jasmine Kaur, Jasleen Kaur, Sanjay Piplani, Harjot Kaur, Harleen Kaur
    Case Reports in Dermatological Medicine.2014; 2014: 1.     CrossRef
  • Cutaneous Metastasis of Medullary Thyroid Carcinoma as the Initial Manifestation of an Otherwise Limited Malignancy: A Case Report
    Sanaz Sanii, Seyed Mohammad Tavangar
    The American Journal of Dermatopathology.2011; 33(7): 716.     CrossRef
  • 9,369 View
  • 67 Download
  • 3 Crossref
Close layer
A Case of Recurrent Solid Pseudopapillary Tumor of the Pancreas with Involvement of the Spleen and Kidney
Sang Eun Park, Nam Sook Park, Jae Min Chun, Nam Whan Park, Young Joon Yang, Gak Won Yun, Hyo Jin Lee, Hwan Jung Yun, Deog Yeon Jo, Kyu Sang Song, Samyong Kim
Cancer Res Treat. 2006;38(2):118-120.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.118
AbstractAbstract PDFPubReaderePub

Solid pseudopapillary tumor of the pancreas (SPTP) is a rare primary pancreatic tumor of an unknown etiology that is usually diagnosed in adolescent girls and young women. Most SPTPs are considered to be benign and only rarely metastasize. We report here on a 27-year old woman with recurrent SPTP with involvement of both the spleen and left kidney at the time of the initial diagnosis, and with aggressive behavior. In July 1995, she was admitted with abdominal discomfort and mass. She underwent exploratory laparotomy with distal pancrea tectomy, left nephrectomy and splenectomy, and was diagnosed with SPTP with invasion to both the spleen and left kidney. In June 2001, she again presented with abdominal pain and was diagnosed as having recurrence of the tumor. She underwent mass excision and omentectomy. Then she was lost to follow-up. In November 2005, she presented once again with an abdominal mass and was diagnosed with recurred SPTP, which formed a huge intraperitoneal mass with peritoneal seeding and the tumor showed multiple metastases in the liver. She is currently being treated conservatively.

Citations

Citations to this article as recorded by  
  • Clinical Pattern of Preoperative Positron Emission Tomography/Computed Tomography (PET/CT) Can Predict the Aggressive Behavior of Resected Solid Pseudopapillary Neoplasm of the Pancreas
    Ji-Su Kim, Emmanuel II-Uy Hao, Seoung-Yoon Rho, Ho-Kyoung Hwang, Woo-Jung Lee, Dong-Sub Yoon, Chang-Moo Kang
    Cancers.2021; 13(9): 2119.     CrossRef
  • 8,157 View
  • 42 Download
  • 1 Crossref
Close layer
Original Articles
A Case of Cardiac Metastasis of Chondrosarcoma
Seung Park Yoo, Bo Yun Chung, Ki Chan Kim, Yeul Hong Kim, Jeong Sik Park, Hyo Jin Lee
J Korean Cancer Assoc. 1994;26(2):345-351.
AbstractAbstract PDF
Metastatic cardiac cancers are more prevalent than generally realized. So prompt recognition is mandatory if any cardiovascular manifestations develop in a patient with a malignant lesion elswhere in the body. Sixty-five year old male patient who had past history of resected chondrosarcoma on the 10th rib of left side presented as a local recurrence and dyspnea. Chest C-T findings demonstrated thrombose on right atrium and superior vena cava. Two-dimensional echocardiographic study showed mild pericardial effusion with a small mass attached to the visceral pericardium and a huge mass occupying nearly entire right atrial chamber with extension to superior vena cava. These findings are suggestive of cardiac metastasis of chon- drosarcoma.
  • 2,804 View
  • 17 Download
Close layer
Determination of Serum CEA Level in Primary Lung Cancer
Jin Hyuk Choi, Jung Hyun Chang, Soon Nam Lee, Eun Mi Nam, Ki Ryung Park, Sa Young Park, Hyo Jin Lee, Sung Min Cho, Young Sun Kim, Ka Eun Woo, Na Young Lee, Na Young Lee, Kwang Ho Kim
J Korean Cancer Assoc. 1996;28(2):281-286.
AbstractAbstract PDF
Background
The role of serum carcinoembryonic antigen(CEA) as a tumor marker in primary lung cancer remains unanswered. Several reports suggested that usefulness of serum CEA was limited to specific histologic types or clinical situations. Methods: Serum levels of CEA were determined in 126 patients with primary lung cancer and its correlation with clinico-pathologic characteristics was investigated. Results: Serum CEA was positive (defined as>5ng/ml) in 71 patients(56.3%). The positivity of serum CEA was significantly higher in adenocarcinoma(72.3%) than that in squamous cell carcinoma(46.5%) and small cell carcinoma(44.0%) (p=0.025). There was no significant difference in positivity of CEA according to sex and stages. Conelueion: Serum CEA does not seem to be standard tumor marker of primary lung cancer. However, it could be useful as prognostic factor or monitor of treatment results, especially in adenocarcinoma.
  • 3,481 View
  • 16 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP